OSE Immunotherapeutics Reports Positive Phase 2 Results for Tedopi in Metastatic Non-Small Cell Lung Cancer

OSE Immunotherapeutics has announced positive topline results from its Combi-TED academic Phase 2 clinical trial, evaluating Tedopi (OSE2101) in combination with either chemotherapy (docetaxel) or anti-PD1 immunotherapy (nivolumab) as a second-line treatment for patients with metastatic Non-Small Cell Lung Cancer (NSCLC). The trial met its primary endpoint, showing a statistically significant 1-year Overall Survival rate of 47% for Tedopi plus docetaxel and 46% for Tedopi plus nivolumab, compared to 29% for docetaxel alone.